Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMX0DUH)

• Drug Name: MEDI2228 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Multiple myeloma	2A83	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMX0DUH

Molecule-Related Drug Atlas

Drug(s) Targeting B-cell maturation protein (TNFRSF17)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Idecabtagene vicleucel	DMP1QTS	Multiple myeloma	2A83	Approved	[3]
Belantamab mafodotin	DMBT3AI	Multiple myeloma	2A83	Approved	[4]
Elranatamab	DMG1MW2	Multiple myeloma	2A83	Approved	[5]
Teclistamab	DMGR8JI	Multiple myeloma	2A83	Approved	[6]
Ciltacabtagene autoleucel	DMU2J7Y	Multiple myeloma	2A83	Phase 3	[7]
Bb2121	DMB0UF9	Multiple myeloma	2A83	Phase 2	[8]
LCAR-B38M CAR-T Cell	DMQZJNA	Multiple myeloma	2A83	Phase 2	[9]
Descartes-08	DM63P1W	Multiple myeloma	2A83	Phase 2	[10]
Descartes-11	DM1UO4S	Multiple myeloma	2A83	Phase 2	[11]
CART-19/BCMA	DMVW1GY	Multiple myeloma	2A83	Phase 1/2	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B-cell maturation protein (TNFRSF17)	TTZ3P4W	TNR17_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT03489525) MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma (MEDI2228). U.S. National Institutes of Health.
• [2] A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma. Leukemia. 2020 Aug;34(8):2150-2162.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [5] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761345
• [6] FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761291.
• [7] ClinicalTrials.gov (NCT04181827) A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4). U.S. National Institutes of Health.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] ClinicalTrials.gov (NCT03758417) A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
• [10] ClinicalTrials.gov (NCT03448978) Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma
• [11] Clinical pipeline report, company report or official report of Cartesian Therapeutics.
• [12] ClinicalTrials.gov (NCT03455972) Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT